Patents by Inventor Frank Blondino

Frank Blondino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080031959
    Abstract: Formulations of an active pharmaceutical agent suitable for oral spray administration for absorption through the oral mucosa and related methods of preparation and administration are provided. Preferred embodiments provide sumatriptan succinate in a potassium phosphate buffer, wherein when a unit dose volume of about 50 to about 600 mcL of the oral spray composition is sprayed, a blood concentration of greater than about 5 ng/ml of sumatriptan is reached within about six minutes post dosing.
    Type: Application
    Filed: July 27, 2007
    Publication date: February 7, 2008
    Inventors: Frank Blondino, Carrie Chen, Howard Malitz, Foyeke Opawale
  • Publication number: 20070248548
    Abstract: Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a viscosity modifying agent, wherein when a unit dose volume of about 25 to 400 mcL of the oral spray composition is sprayed, the spray has a median particle size diameter of about 40 to about 100 microns.
    Type: Application
    Filed: April 19, 2007
    Publication date: October 25, 2007
    Inventors: Frank Blondino, Howard Malitz
  • Publication number: 20050079137
    Abstract: A liquid aerosol formulation comprising at least one thermally stable active ingredient selected from the group consisting of butalbital, lorazepam, ipratropium, baclofen, morphine, scopolamine, pharmaceutically acceptable salts and esters thereof and derivatives thereof. The liquid formulation can include an organic solvent such as propylene glycol and one or more optional excipients. The active ingredient can be present in an amount of 0.01 to 5 weight percent and the formulation can be heated to provide a vapor which forms an aerosol having a mass median aerodynamic diameter of less than 3 ?m.
    Type: Application
    Filed: October 6, 2004
    Publication date: April 14, 2005
    Inventors: Frank Blondino, Justin Poklis, Matthew Baker
  • Patent number: 5508023
    Abstract: 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) has been identified as a highly polar propellant. Surfactants which have an elevated value (9.6 or greater) for their hydrophilic-lipophilic balance (HLB) can be used as suspending, wetting, and lubricating agents or cosolvents in metered dose inhaler (MDI) formulations pressurized with HFC-227 or propellant blends that contain HFC-227. Particularly preferred surfactants include polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan mono-oleate, polyethylene glycol 300, propoxylated polyethylene glycol, polyoxyethylene 4 lauryl ether, and diethylene glycol monoethyl ether.
    Type: Grant
    Filed: April 11, 1994
    Date of Patent: April 16, 1996
    Assignees: The Center for Innovative Technology, Virginia Commonwealth University
    Inventors: Peter Byron, Frank Blondino